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The moment you know…
[David Bowie (1947–2016)]
When editor-in-chief Carol Isaacson Barash asked me to edit a
special issue of Applied & Translational Genomics dedicated to personal
genomics, I was excited but not sure where to begin. I had tried to
chronicle the early, heady days of individuals gaining access to their
own genomic information circa 2007–2010 (Angrist, 2010), but some-
how somuch and so little have happened since then: was the narrative
to be one of seismic shift (thanks to increasingly cheap genotyping/
sequencing and the concomitant growth of personal genomics data-
bases) or boring stasis/retrenchment (thanks to still-missing heritability
and regulatory clampdowns)?
Consequently, I opted to refrain from imposing some kind of over-
arching theme and rather, approached it as a “hypothesis-free” experi-
ment. We solicited papers from a range of researchers, scholars and
patient activists (and the broader genomics community) with the only
prerequisite being that they submit something about which they were
passionate and could speak to with some authority, whether that au-
thority stemmed from empirical data or personal experience (or both).
In hindsight it seems clear that, with respect to personal genomics,
the answer to the late greatMr. Bowie's question ismanifold: like a pro-
miscuous electron,we are in several places at once, some promising and
some problematic (and some both).
1. The perceived value of personal genomics
The prospect of having access to one's own DNA information
brought with it sometimes heated debate about what practical pur-
poses, if any, such information was good for. Most of us agreed—and
the data showed—that it was not dangerous (Bloss et al., 2013). Okay,
but could it, by itself, be predictive of health outcomes for complex
diseases? Many of us bcoughN wanted to believe that it could be. But
nearly a decade and well over a million people into this, we are left to
conclude that, with few exceptions, the predictive power of chip-
based personal genomics for complex traits amounts to fairly weak
sauce (Jordan, 2014; Wray et al., 2013).
But if that is the case, thenwhy dousers continue to purchase direct-
to-consumer genetic tests (Servick, 2015)? (And why have the largest
commercial players in DNA sequencing technology and genealogy
made major strategic moves toward DTC genomics (Anonymous,
2015; Hernandez, 2015)?) In their paper Mauro Turrini and Barbara
Prainsack address the consumer paradox head on (Turrini and
Prainsack, 2016). They broach potential health implications and the
fraught notion of “personal utility” (e.g., the purchase of longterm carehttp://dx.doi.org/10.1016/j.atg.2016.01.010
2212-0661/© 2016 The Author. Published by Elsevier B.V. This is an open access article underinsurance upon discovering one's greater risk for Alzheimer's disease
(Taylor et al., 2010)). Turrini and Prainsack eschew discussion of the
tired sawhorse of “actionability” in favor of an exploration of the intrin-
sically social nature of personal genomic data and its relationships to
family, ancestry and the research community.
Elsewhere, LauraMählmann, Effy Vayena and colleagues describe the
results of a survey of Swiss adults over the age of sixty (Mählmann et al.,
2016). Their ﬁndings reveal a lingering generational divide: only one-
third of respondents were familiar with personal genomics, while nearly
half were not interested in undergoing such testing because they thought
the results might be worrisome or they harbored concerns about the va-
lidity of the tests. Of thosewhowanted to participate in personal genomic
testing, the number one reason for wanting to take part was to learn
about their own health risks, followed by a desire to contribute to re-
search. Turrini and Prainsack ﬂagged the latter as well (and 23andMe
has certainly noticed), yet it is a motive that often goes overlooked and
is deserving of more attention.2. The uncertain bargain
Internet commerce has been crucial to the rise of commercial
DTC genomics. The ability to click—and pay—seamlessly means that it
is much easier to build a database of more than a million customers
than it would be if one had to rely on the postal service or brick-and-
mortar stores.
But what exactly have we million agreed to by clicking? Beyond
sending our credit card information in exchange for parsed genotypes,
what does accepting a DTC company's terms of service actually mean?
Two papers in this issue reveal why the answer is not always clear.
Andelka Phillips offers an overview of the DTC genetic testing land-
scape (which now extends far beyond health-related and ancestry test-
ing to forensics, diet, inﬁdelity and matchmaking) and the regulatory
challenges posed by it (Phillips, 2016). She describes the industry's reli-
ance on so-called wrap contracts that, in some cases, do not even re-
quire the consumer to open the link to the actual contract, let alone
read it, before clicking “I agree.” Of course most of us decline to read
terms of service anyway (Böhme and Köpsell, 2010). But in an increas-
ingly hackable post-Snowden world, do we do so at our peril?
The work of Emilia Niemiec and Heidi Howard suggests that even a
close reading of such terms might not always lead to informed purchas-
ing decisions. The authors scrutinized the websites of four North
American companies offering whole-genome and/or whole-exome se-
quencing to consumers (Niemiec and Howard, 2016). They found that
while these companies have upped their gamewith respect to data secu-
ritymeasures, they remain less than fully transparent about their policiesthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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3. Who gets to know: access and disclosure
While large-scale sequencing and genotyping have become routine,
unfettered sharing of the information with those individuals from
whom the samples and data came has not. As I′ve written elsewhere,
this is unfortunate (Angrist, 2011; Angrist, 2016). Not only does it per-
petuate notions of genetic exceptionalism, it belies the ethos of partner-
ship that, in the dawning era of precision medicine, is suddenly au
courant. This frustration is palpable in the commentary an anonymous
author sent me, in which she describes the gauntlet she had to run for
a period of months before getting access to her extended exome report
(Anonymous, 2016).
Which is why places like Geisinger Health System deserve credit
for walking the return-of-results walk. In their commentary, Andy
Faucett and Dan Davis recount the origins of Geisinger's decision to
share secondary ﬁndings with patients undergoing whole-genome/
whole-exome sequencing (Faucett and Davis, 2016). Unlike other
large-scale genomic initiatives (I′m looking at you, publicly fundedMil-
lion Veteran Program (Gaziano et al., 2015; Kaufman et al., 2012)),
when patients and participants said they wanted their genomic results,
Geisinger actually listened. And perhaps the tide is turning: As of early
2016, 23andMe was set to launch a program whereby academic re-
searchers could return the company's product to their research partici-
pants (J. Hagenkord, personal communication).
Of course, the implications of genetic information are not limited ei-
ther to isolated individuals or to health per se. Particularly if it refutes
presumptive biological relationships, DNA can upend family dynamics
in profound and sometimes tragic ways (Doe, 2014). This has been
the primary hitherto justiﬁcation for genetics professionals not to dis-
close misattributed paternity to patients—indeed nondisclosure has
been the norm for many decades. But in their bold and provocative
paper, Laura Hercher and Leila Jamal make compelling arguments for
rethinking the status quo (Hercher and Jamal, 2016). Not only is genetic
testingmore sophisticated, so too are those undergoing such testing. As
the authors note, “In an age where we are counseling our patients to
empower themselves by understanding their own health risks and sus-
ceptibilities, we cannot rely on misdirection and sleight of hand to hide
pertinent facts fundamental to their biological selves.” (Hercher and
Jamal, 2016).
4. Self-starters: exploration, alienation and determination
For patient activists, the stakes—often a desperately ill child with an
unknown causative genetic variant and/or limited treatment options—are
obviously much higher. For them, personal genomics is excruciatingly
personal.
In separate commentaries, both Terry (2016) andCollins (2016)
point up the challenges faced by parents of children with serious rare
conditions. Initially, at least, neither authorwished to go around the sys-
tem but rather to work within it—to champion it and help it to grow…
yet time and again both have found themselves ignored or even
thwarted by it. Terry describes her shock and horror at discovering a
human genetics ecosystem that often placed professional advancement
ahead of patient needs (Terry, 2016). For her part, Collins laments that
the same enthusiasm and resources dedicated to sequencing are not
brought to bear on what comes after the diagnosis (Collins, 2016).
Both she and Terry are determined to “raise the stature of phenotype,”
in part by aggregating parent observations of their children (another
word for this is “data”). Will the medical community ﬁnally learn to
heed them?
Hugh Rienhoff's story iswell known tomany, having been told in the
pages ofNature (Maher, 2007) andWired (Koerner, 2009), among other
places. In this issue he offers a ﬁrst-person account of an arduousdecade-long diagnostic odyssey and of the many heroic people he en-
listed and the sometimes maddening obstacles he encountered en
route to identifying his daughter Bea's TGFβ3 mutation (Rienhoff,
2016). Rienhoff's unique background as a former medical geneticist
and current head of a startup developing therapies for genetic diseases
affords him a singular perspective on the art and science of diagnostic
sleuthing and the biology underlying Mendelian conditions. And he
clearly recognizes the varied incentives that drove people to help his
family and, occasionally, to turn away from them.
Rienhoff also reminds us of a couple of other things. The ﬁrst is how
hard it is to navigate the terrain of the undiagnosed under any circum-
stances: having a personal stake and access to intellectual and techno-
logical resources can shorten the time to answers, but the road
remains long and circuitous. As a colleague of mine likes to say, these
studies are never over.
The second is about how we view ourselves. Many of us
have championed access to genetic information for a long time for
many valid reasons: for our health, yes, but also for reproductive
decisionmaking, STEM education and, as mentioned, as a means to par-
ticipate in and contribute to research. But increasingly we recognize
its limitations. However vivid our deterministic dystopian fantasies,
without phenotype, environment and trait data, a genome is a pathetic
proxy for what makes a human being.
So as we celebrate quantum advances in sequencing, wring our
hands over missing heritability and inadequate databases, negotiate
fraught questions of genetic access and disclosure, and embark on in-
creasingly ambitious “moonshots,” perhaps we might also the most
adaptive phenotype of the last decade: humility.
As Hugh Rienhoff says of his daughter, “She is so much more than
her DNA.”
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